Association between bone turnover markers, BMD and height loss of cemented vertebrae after percutaneous vertebroplasty in patients with osteoporotic vertebral compression fractures

Shangjin Lin1†, Xiaoxi Cai1†, Qun Cheng2, Cong Chen1, Xuhai Cao1, Fengjian Yang1 and Yongqian Fan1∗

Abstract

Introduction: Percutaneous vertebroplasty (PVP) was recently performed for treating patients with osteoporotic vertebral compression fractures (OVCF). However, recompression of cemented vertebra with significant vertebral height loss occurred in the patients after PVP was observed during the follow-up period. The purpose is to explore the risk factors among several potential predictors for the height loss of treated vertebral bodies after PVP in patients with OVCF.

Methods: A study of 93 patients who had undergone PVP between May 1, 2016, and March 1, 2019, at the Spine Center of Huadong Hospital Affiliated to Fudan University was conducted. The fractured vertebral height loss ratio ≥ 15% at final follow-up were defined as cemented vertebra recompression. The following variables were measured and collected: age, gender, body mass index (BMI), bone mineral density (BMD), volume of bone cement injected, bone cement leakage, fractured vertebra segment, contact between bone cement and endplates, serum of calcium and phosphorus, and six kinds of bone turnover markers.

Results: Mann-Whitney U test and Univariate Logistic regression analysis showed that the cemented vertebra recompression was correlated with BMD, contact between bone cement and endplates, parathyroid hormone (PTH), and 25-hydroxy vitamin D3 (25-OH-D3). Following multivariate modeling, multiple factors logistic regression elucidated that high BMD (P < 0.001, OR = 0.089) and high level of serum 25-OH-D3 (P = 0.012, OR = 0.877) were negatively correlated with the cemented vertebra recompression after PVP.

Conclusion: Decreased BMD and lower level of serum 25-OH-D3 might be two critical and significant risk factors for the height loss of cemented vertebrae after PVP.

Keywords: BMD, Percutaneous vertebroplasty, 25-OH-D3, Osteoporotic vertebral compression fracture, Cemented vertebra recompression

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
osteoporosis or osteopenia [1, 2]. The conservative treatments for OVCF include non-weight-bearing bed rest, orthosis use, and drug treatment. The use of spinal orthoses plays a certain role in maintaining spinal stability and limiting progression of the deformity [3]. However, despite proper conservative treatment, OVCFs also result in some complications among the elderly population, such as deep vein thrombosis, progressive kyphosis, impaired gait, decreased pulmonary function, and urinary system infection [4].

As these problems in lives decline in the quality of life, a more effective treatment should be created. Percutaneous vertebroplasty (PVP), used to treat vertebral angioma, was initially introduced in the radiology literature in 1987 [5]. Then PVP is widely used to treat back pain associated with OVCF, as it makes significant pain relief, and patients get the early mobilization [6]. It is generally accepted as a minimally invasive technique, which can structurally stabilize a fractured vertebral body through the injection of self-curing cement substance and make practical importance for reducing the back pain due to the OVCF. During follow-up of our patients, however, we observed the height loss of augmented vertebrae after PVP, which might result in the aggravation of local kyphotic deformity and new pain from the recompression of the cemented vertebrae. Consequently, it has significant importance of investigating the risk factors for such height loss result from the cemented vertebrae; nevertheless, few reports discussed the risk factors of significant vertebral height loss after PVP, and many results have been controversially caused by the limited data and a lack of the unique standard measurement of vertebral height and evaluation for the rate-of-change of vertebral height [7, 8].

It has a broad consensus that recompression of an augmented vertebra could frequently occur after PVP, and the probability of recompression is increasing with the increasing application of PVP [9, 10]. The representative risk factor associated with recompression after PVP is osteoporosis; other factors associated with the vertebral height loss include the cemented volume, advanced age, bone mineral density, the distribution pattern of cement injected into the fractured vertebra, and contact between bone cement and upper-lower endplates [9, 11, 12]. However, these studies did not include such vital factors associated with osteoporosis as bone turnover markers, including parathyroid hormone (PTH), C-terminal telopeptide of type I collagen (β-CTX), N-terminal propeptides of type I procollagen (PINP), osteocalcin (OC), serum 25-hydroxy vitamin D3 (25-OH-D3) levels, and alkaline phosphatase (ALP). Bone turnover markers are parameters reflecting the dynamic status of osteoporosis. This means that the bone mineralization and bone transformation in OVCF patients can be indirectly understood by detecting serum bone metabolism indexes. The authors hypothesized that there was a certain correlation between bone turnover markers and postoperative cemented vertebral height loss. Therefore, this study aimed to investigate the association of the risk factors, including bone metabolism markers, with the cemented vertebra recompression. It was also the first report in the literature to study the correlation between serum bone metabolism indexes and cemented vertebra recompression, providing clues for further clarifying the risk factors of cemented vertebra recompression.

Materials and methods
Study participants
Of those subjects who suffered from fresh compression fracture on only one spinal segment between May 1, 2016, and March 1, 2019, at the institution of Spine Center in our hospital, 109 consecutive patients were analyzed. Sixteen patients were excluded from the study, including three patients who died of unrelated disease within two months, five patients who underwent new vertebral fractures observed at adjacent levels, and eight patients who had not enough X-ray radiographs and refused to take examinations at our outpatient clinic. All patients had used thoracic-lumbosacral orthosis after PVP for more than one month and took medication prescribed for osteoporosis (Alendronate Sodium and Vitamin D3, one tablet/week) and kept proper comparable radiological images during the time of follow-up. This study was approved by the Institutional Ethics Committee of Huadong Hospital Affiliated to Fudan University. All participants in the study received written and oral information prior to giving written consent, and the study was performed following the Declaration of HELSINKI.

Inclusion and exclusion criteria
Inclusion criteria were as follows: (1) single-level OVCF and the fractured segment was at T6 or lower; (2) fresh fractures that all patients’ collapsed vertebral bodies had the presence of bone marrow edema on magnetic resonance imaging (MRI) T2-weighted short tau inversion recovery sequences; (3) age over 60 years; (4) no severe surgical complications, for example, post-operative neurologic deficit because of the cement leakage; and (5) patients’ back pain caused by OVCF with ache on percussion of the fracture vertebral spinous position. Exclusion criteria were (1) non-osteoporotic vertebral compression fracture related to pathologic issue, infection, and malignancy; (2) multiple-level OVCFs; (3) severe significant neurologic deficit before and after surgery; (4) life-threatening complication after PVP, such as systemic infection, pulmonary embolism, or hypostatic pneumonia; and (5)
occurrence of new vertebral fracture observed at adjacent levels after PVP.

**Surgical procedure**
PVP was performed within three days of hospitalization for all patients. The previous report described the operation previously in detail; besides, every operation was conducted by the specified spinal surgeons with sufficient clinical experience, and the skills designed by Garfin et al. [13]. The patients first placed in a prone position on the operating table were administered under local anesthesia (2% lidocaine). With the guidance of two single-plane mobile C-arms, the anterior–posterior and lateral views of the fractured vertebra were confirmed. After incision of the skin, two 11-gauge needles were placed parallel to the superior and inferior edges of the pedicle, percutaneously into the anterior part of the vertebral body with a transpedicular or perpendicular approach. The injection of polymethylmethacrylate (PMMA) cement (Stryker, Kalamazoo, USA) into the fractured vertebral body was ceased until the cement reached the posterior one-fourth of the body or if PMMA extravasated outside the bone. The volume of bone cement inserted during the operation for each vertebra was recorded. Thoracic-lumbar sacral orthosis were supplied to all patients for one month, and osteoporotic medications were used postoperatively.

**Radiological data collection and assessment**
To analyze and evaluate the radiological results of PVP, pre-operative, immediately post-operative, and final follow-up X-ray radiographs of each patient were collected. The follow-up period was no more than one year. The anterior body height of the fractured vertebrae and the upper and lower adjacent fractured vertebrae were measured in lateral X-ray films. The prone lateral radiographs were substituted for standing lateral radiographs at three point-in-time of pre-operative, immediately post-operative, and the last follow-up because of film unavailability. Vertebral height measured immediately post-operative maybe not be under the same condition when measured on the last follow-up radiograph because of magnification error created by inconsistencies in patient positioning and tube-to-film distance. Because the original height of fractured vertebrae was closer to the average anterior height of the upper and lower adjacent vertebrae [14], in order to more accurately reflect the height changes of the vertebral body, we introduced an index of the anterior vertebral height ratio (AVHR) which was expressed as a percentage of the fractured vertebral height divided by adjacent fractured vertebral height instead of an absolute numerical value of the fractured vertebral height in our previous study [15]. The fractured vertebral height loss ratio (FVHLR) was calculated by subtracting the immediately post-operative AVHR from the last follow-up AVHR. All the height values were measured twice by two radiologists individually and independently in order to eliminate intra-and inter-observer bias to the utmost. All radiologic measurements were checked digitally using the picture archiving and communication system.

**Grouping and clinical study**
The cemented vertebra recompression after PVP was regarded as the FVHLR ≥ 15% during follow-up [11, 16]. Patients who did not meet the above criteria within a one-year follow-up period were considered non-recompression after PVP. According to the above standard, the participants were divided into 32 patients in the recompression group and 61 patients in the non-recompression group. The scores of the total hip bone mineral density (BMD) of each patient were measured using dual-energy X-ray absorptiometry to determine the extent of osteoporosis before the operation, and the average BMD score was analyzed by excluding the BMD scores of the patient who differed by more than one standard deviation from the other one. Laboratory investigations including serum bone alkaline phosphatase (ALP), serum of calcium and phosphorus, and bone metabolism markers were performed on the morning following hospitalization for all subjects. We, respectively, regarded PTH, β-CTX, PINP, OC, 25-OH-D3, and ALP as markers of bone turnover. Age, gender, BMI, the volume of bone cement injected, leakage of bone cement, fractured vertebra segment, contact between the bone cement and the endplates and the medication history were also documented.

**Statistical analysis**
All analyses were performed using IBM SPSS software for Windows version 23.0 (SPSS, Chicago, IL, USA). Firstly, continuous variables (BMD, Serum calcium and phosphorus, ALP, Volume of bone cement injected, PTH, β-CTX, PINP, OC, 25-OH-D3 levels) were checked to determine whether they were normally distributed. As these variables were not normally distributed, Mann–Whitney U test was used to examine the association between these variables in patients with and without cemented vertebra recompression. We converted the continuous variables such as age and BMI into categorical variables. Univariate Logistic regression analysis was used to determine the association between the cemented vertebra recompression and each categorical variable. Variables with a significant probability of $P<0.25$ were then included in the multivariate logistic regression analysis [17]. Corresponding 95% confidence limits (CIs) were reckoned with confidence interval estimation, and $P<0.05$ was statistically significant.
Results

Univariate analysis of variables related to the cemented vertebra recompression after PVP

The continuous variance analysis was performed using Mann–Whitney U test, indicating that a significant difference has been observed between the recompression group and non-recompression group in BMD, serum PTH, and serum 25-OH-D3, and the difference was statistically significant ($P<0.05$) (Fig. 1). The T value of BMD in the non-recompression group ($\text{median} = -1.1, \text{IQR} = -2.1 \text{ to } -0.3$) was significantly higher than that in the recompression group ($\text{median} = -2.8, \text{IQR} = -3.1 \text{ to } -2.25$), and the difference was statistically significant ($Z \text{ value} = 6.189, P<0.001$). Similarly, the level of serum PTH and 25-OH-D3 in the non-recompression group were 48.9 pg/ml ($\text{IQR} = 38.3–61.6 \text{ pg/ml}$) and 18.2 ng/ml ($\text{IQR} = 12.3–22.9 \text{ ng/ml}$), respectively, and the level of serum PTH and 25-OH-D3 in the recompression group were 38.1 pg/ml ($\text{IQR} = 26.7–50.3 \text{ pg/ml}$) and 13.3 ng/ml ($\text{IQR} = 10.45–18.5 \text{ ng/ml}$), respectively, with statistically significant differences between the two groups ($Z \text{ value} = 2.952, 2.252, P=0.003, 0.024$). The specific analysis results are shown in Table 1.

Univariate logistic regression analysis showed that the cemented vertebra recompression after PVP was correlated with whether the bone cement is in contact with the endplates, and the correlation was statistically significant (odds ratio 0.265, 95% CI 0.103–0.682, $P=0.006$). There was no significant correlation in gender, BMI, age, fracture segment, bone cement volume, the medication history, and whether the bone cement is leakage, as showed in Table 2.

Multivariate logistic regression analysis of the factors related to the cemented vertebra recompression after PVP

Based on the result of univariate logistic regression analysis and Mann–Whitney U test, variables with a significant probability of $P<0.25$ were put into the following multivariate logistic regression analysis. Therefore, seven variables, including BMD, ALP, P1NP, PTH, 25-OH-D3, $\beta$-CTX, contact between bone cement and endplates, were included in the multivariate logistic regression model. Among them, high BMD (odds ratio 0.089, 95% CI 0.026–0.306, $P<0.001$) and high level of serum 25-OH-D3 (odds ratio 0.877, 95% CI 0.792–0.971, $P=0.012$) were negatively correlated with the cemented vertebra recompression after PVP, which were the protective factors ($B<0$). The specific analysis results are shown in Table 3.

Discussion

OVCFs are common among older Chinese adults, especially postmenopausal women due to bone loss caused by estrogen deficiency. The back pain, the kyphotic deformity, and the disability to be moved resulting from OVCFs have long motivated the search for effective techniques. As a result, PVP and percutaneous balloon kyphoplasty (PKP) have been suggested as effective and minimally invasive procedures for OVCFs [18, 19]. The PKP is an analogous technique to PVP, but it has an additional step of expanding balloons via bilateral transpedicular approach in the vertebrae to create cavities before injection of cement [20]. Some researchers have indicated that PKP is more effective and safer to restore the vertebral height than that of PVP [21]. However, we found that further recompression of cement vertebrae with significant vertebral height loss and aggravated local kyphotic deformity occurred more frequently in the patients after PKP during the follow-up period. Kim et al. [22] suggested that treated vertebral height loss was more prominent in PKP than in PVP, which was consistent with our clinical conclusion. They thought that PMMA filled the cancellous portion of the vertebrae with an interdigitated pattern in PVP, which was easier to transmit the
load from the upper endplate to the lower one. In contrast, PMMA is not interdigitated but consists of one or two solid masses in PKP. Besides, the increased restoration of the fractured vertebral height by PKP could promote soft-tissue tension around the vertebrae, leading to an increasing loading adjacent to the cemented vertebrae, which can exacerbate the height loss of the treated vertebrae and the occurrence of adjacent vertebral fractures. Hence, we chose PVP to treat the OVCFs instead of PKP gradually.

It is widely accepted that the recompression of cemented vertebrae frequently occurred after PVP, typically within six months after invasive surgery based on our clinical observation. However, what are the critical factors related to inducing height loss of previously treated vertebrae after PVP is uncertain. Therefore, we conducted a detailed analysis of potential risk factors for height loss of cemented vertebrae, especially the bone metabolism markers, which are analyzed as the risk factors associated with cemented vertebral height loss for the first time.

The presence of non-PMMA-endplate-contact might play an essential role in inducing recompression after PKP treated vertebrae [9]. In addition, the distance between PMMA and endplate was an important risk factor for the recompression of cemented vertebrae after PKP, and the recompression of cemented vertebral height was positively correlated with the distance between PMMA and endplate [23]. Besides, Zhang et al. emphasized that the contact between bone cement and upper-lower endplates was an important independent protective factor for the recompression of cemented vertebrae after percutaneous vertebral augmentation [11]. Similar to the previous studies, this research indicated that the recompression

| Table 1 Comparison of continuous variables of patients between two groups (the Mann–Whitney U test) |
|---------------------------------------------------------------|
| Clinical parameters                                           | Mean rank | Median | IQR    | Z score | P value |
| The volume of bone cement injected                            |           |        |        |         |         |
| Recompression group                                           | 45.55     | 5.5    | 4.5–6.0 | −0.381  | 0.703   |
| Non-recompression group                                       | 47.76     | 5.25   | 5.0–6.0 |          |         |
| BMD                                                           |           |        |        |         |         |
| Recompression group                                           | 23.11     | −2.8   | −3.1 to −2.25 | −6.189 | <0.001* |
| Non-recompression group                                       | 59.53     | −1.1   | −2.1 to −0.3 |         |         |
| Serum calcium                                                 |           |        |        |         |         |
| Recompression group                                           | 43.08     | 2.22   | 2.2–2.3 | −1.070  | 0.285   |
| Non-recompression group                                       | 49.06     | 2.2    | 2.1–2.3 |          |         |
| Serum phosphorus                                              |           |        |        |         |         |
| Recompression group                                           | 46.17     | 1.135  | 0.985–1.23 | −0.214 | 0.830   |
| Non-recompression group                                       | 47.43     | 1.13   | 1.01–1.24 |         |         |
| ALP                                                           |           |        |        |         |         |
| Recompression group                                           | 41.23     | 75     | 61.5–96 | −1.492  | 0.136   |
| Non-recompression group                                       | 50.02     | 85     | 69–102  |          |         |
| β-CTX                                                         |           |        |        |         |         |
| Recompression group                                           | 51.75     | 613.1  | 476–782.6 | −1.229 | 0.219   |
| Non-recompression group                                       | 44.51     | 516.4  | 391–721.4 |         |         |
| OC                                                            |           |        |        |         |         |
| Recompression group                                           | 48.91     | 15.25  | 9.9–21.3 | −0.493  | 0.622   |
| Non-recompression group                                       | 46        | 13.4   | 9.7–18.2 |          |         |
| P1NP                                                          |           |        |        |         |         |
| Recompression group                                           | 41.78     | 43.45  | 28.5–57.3 | −1.351 | 0.177   |
| Non-recompression group                                       | 49.74     | 51.6   | 36.6–67.4 |         |         |
| PTH                                                           |           |        |        |         |         |
| Recompression group                                           | 35.59     | 38.1   | 26.7–50.3 | −2.952 | 0.003*  |
| Non-recompression group                                       | 52.98     | 48.9   | 38.3–61.6 |         |         |
| 25-OH-D3                                                      |           |        |        |         |         |
| Recompression group                                           | 38.3      | 13.3   | 10.45–18.5 | −2.252 | 0.024*  |
| Non-recompression group                                       | 51.57     | 18.2   | 12.3–22.9 |         |         |

* and bold indicate statistically significant findings
### Table 2  Comparison of categorical variables of patients between two groups (Univariate Logistic regression analysis)

| Clinical parameters                                      | Cemented vertebra recompression | B value | SE value | Wald value | OR (95%CI)      | P value |
|----------------------------------------------------------|---------------------------------|---------|----------|------------|----------------|---------|
| Sex                                                      |                                 |         |          |            |                |         |
| female                                                   |                                 | 0.279   | 0.584    | 0.229      | 1.322 (0.421–4.152) | 0.632   |
| male                                                     |                                 | 1       |          |            |                |         |
| BMI                                                      | overweight                      | 0.280   | 0.447    | 0.393      | 1.321 (0.551–3.178) | 0.531   |
|                                                          | normal weight                   | 1       |          |            |                |         |
| Age                                                      | super-advanced age(>80 years)   | 0.433   | 0.440    | 0.967      | 1.542 (0.651–3.653) | 0.325   |
|                                                          | advanced age(60–80 years)       | 1       |          |            |                |         |
| Contact between bone cement and the endplates            | YES                             | −1.329  | 0.483    | 7.578      | 0.265 (0.103–0.682) | 0.006*  |
|                                                          | NO                              | 1       |          |            |                |         |
| Bone cement leakage                                      | YES                             | 0.096   | 0.489    | 0.038      | 1.101 (0.422–2.871) | 0.845   |
|                                                          | NO                              | 1       |          |            |                |         |
| Fractured vertebra segment                               | Thoracic region                 | −0.431  | 0.554    | 0.604      | 0.650 (0.220–1.925) | 0.437   |
|                                                          | Lumbar region                   | 0.360   | 0.579    | 0.386      | 1.433 (0.461–4.456) | 0.535   |
|                                                          | Thoracolumbar region             | 1       |          |            |                |         |
| The use of antihypertensive drugs                        | YES                             | 0.172   | 0.439    | 0.154      | 1.188 (0.503–2.807) | 0.695   |
|                                                          | No                              | 1       |          |            |                |         |
| The use of hypoglycemic drugs                            | YES                             | −0.255  | 0.546    | 0.219      | 0.775 (0.266–2.258) | 0.640   |
|                                                          | No                              | 1       |          |            |                |         |
| The use of antiplatelet drugs                            | YES                             | −0.152  | 0.521    | 0.086      | 0.859 (0.309–2.383) | 0.770   |
|                                                          | No                              | 1       |          |            |                |         |
| The use of antiarhythmic drugs                           | YES                             | −0.817  | 0.823    | 0.986      | 0.442 (0.088–2.216) | 0.321   |
|                                                          | No                              | 1       |          |            |                |         |

* and bold indicate statistically significant findings

### Table 3  Risk factors related to the cemented vertebra recompression after PVP in OVCF patients (Multivariate logistic regression analysis)

| Clinical parameters            | B value | SE value | Wald value | P value | OR value | 95%CI     |
|-------------------------------|---------|----------|------------|---------|----------|-----------|
| Bone cement distribution      | −1.241  | 0.766    | 2.623      | 0.105   | 0.289    | 0.064–1.298 |
| BMD                           | −2.419  | 0.63     | 14.743     | <0.001* | 0.089    | 0.026–0.306 |
| PTH                           | −0.027  | 0.024    | 1.274      | 0.259   | 0.973    | 0.929–1.02 |
| 25-OH-D3                      | −0.131  | 0.052    | 6.332      | 0.012*  | 0.877    | 0.792–0.971 |
| P1NP                          | −0.005  | 0.017    | 0.077      | 0.782   | 0.995    | 0.963–1.029 |
| ALP                           | −0.027  | 0.014    | 3.679      | 0.055   | 0.973    | 0.947–1.001 |
| β-CTX                         | −0.001  | 0.002    | 0.41       | 0.522   | 0.999    | 0.995–1.002 |

* and bold indicate statistically significant findings
of cemented vertebra after PVP was correlated with the contact between bone cement and upper/lower endplates (odds ratio 0.265, 95% CI 0.103–0.682, P = 0.006). Hence, we suggested that spinal surgeons might fill the treated vertebrae with adequate cement, which requires the cement should contact with upper-lower endplates during the surgical process. An et al. argued that the more bone cement injected, the lower incidence of augmented vertebra recompression occurred after PVP [9], while we found no correlation between bone cement volume and cemented vertebra recompression in this study.

High bone turnover was a risk factor for new fractures for patients with osteoporosis [24]. Nonetheless, there were few reports for analyzing the relationship between bone turnover and height loss of cemented vertebrae. Komemushi et al. [25] suggested that the combination of high levels of bone resorption markers and normal levels of bone formation markers might be associated with the increasing risk of new recurrent fractures after PVP. This research only concerned the association between bone turnover markers and new recurrent fractures but not the recompression of treated vertebrae; moreover, the number of their investigated subjects was only 30, and their bone turnover examination just included urinary β-CTX and serum ALP. In the present study, we considered the serum bone metabolism markers containing PTH, β-CTX, PINP, osteocalcin, 25-OH-D3 levels, and ALP as predictive risk factors for the cemented vertebral height loss. Our findings revealed that the level of serum PTH of cemented vertebra recompression group (median = 38.1 pg/ml, IQR = 26.7–50.3 pg/ml) was lower than that of non-recompression group (median = 48.9 pg/ml, IQR = 38.3–61.6 pg/ml, P = 0.003). As all we know, PTH could regulate the level of calcium in serum and increase bone formation through stimulating osteoblasts to produce local regulatory factors and regulating bone growth by mediating the proliferation and differentiation of osteoblasts [26, 27]. If applied intermittently, PTH could build new bone by constantly stimulating the receptor activator of the nuclear factor [28]. Yang et al. [29] found that PTH (1–34) was a safe and effective to improve vertebral BMD at onset time, growth rate and range in the treatment of primary osteoporosis [28]. Hence, we suggested that vitamin D supplementation was necessary for fracture healing and cemented vertebra height maintenance.

As a consensus, decreased BMD is a general known risk factor for fractures, and recent studies have found that decreased bone density is the leading cause of re-fracture of cemented vertebra and adjacent vertebra after PVP [37–39]. Similar to the previous researches, we
found that the T value of BMD of cemented vertebra recompression group (median = −2.8, IQR = −3.1 to −2.25) was lower than that of the non-recompression group (median = −1.1, IQR = −2.1 to −0.3, P < 0.001). In addition, high BMD (P < 0.001, OR = 0.089) was negatively correlated with the recompression of cemented vertebra after PVP, meaning that patients with decreased BMD had a high risk of cemented vertebrae recompression. Besides, Yang et al. [40] also reported that decreased BMD was a decisive risk factor for persistent back pain after PVP in OVCF patients. Therefore, BMD might play an essential role in the height loss of treated vertebrae, and positively anti-osteoporosis treatment is needed for elderly OVCF patients after PVP.

Limitations
The present study has its limitations due to the number of subjects is not large based on the strict exclusion and inclusion criteria for patient selection. Moreover, the follow-up period is relatively short, while a longer follow-up time is necessary to determine the risk factors for height loss of treated vertebral bodies after PVP. Some new technologies, such as combined intravoxel incoherent motion diffusion-weighted MR imaging and magnetic resonance spectroscopy, have not been employed to differentiate osteoporotic fractures from osteolytic metastatic vertebral compression fractures in this study [41]. Finally, every patient’s daily activity is not controlled entirely in follow-up period after PVP. As the intensity of their daily activities increases, the mechanical pressure significantly increased upon cemented vertebrae, which might accelerate fractured vertebral height loss. Well-designed research using extensive materials would be helpful in terms of further evaluating the height loss of cemented vertebrae after PVP.

Conclusion
In light of our results, we concluded that decreased BMD and lower level of serum 25-OH-D3 might be two critical risk factors for the height loss of cemented vertebrae after PVP. For elderly patients with OVCF undergoing PVP surgery, it is necessary to detect the level of serum 25-OH-D3 before surgery, which avails for evaluating and predicting the risks of postoperative cemented vertebrae recompression.

Authors’ contributions
YQF designed the research and revised the manuscript. SJL and XXC contributed to analysis and drafting the manuscript. QC, CC, XHC, and FYJ participated in data collection and patients’ follow-up. All authors read and approved the final manuscript.
Zhang L, Wang Q, Wang L, Shen J, Zhang Q, Sun C. Bone cement distribution in the vertebral body affects chances of recompensation after percutaneous vertebroplasty treatment in elderly patients with osteoporotic vertebral compression fractures. Clin Interv Aging. 2017;12:431–6. https://doi.org/10.2147/CIA.S113246.

10. Takahara K, Kamimura M, Moriya H, Ashizawa R, Koike T, Hida Y, Ikegami S, Nakamura Y, Kato H. Risk factors of adjacent vertebral collapse after percutaneous vertebroplasty for osteoporotic vertebral fracture in postmenopausal women. BMC Musculoskelet Disord. 2016;17:12. https://doi.org/10.1186/s12891-016-0887-0.

11. Gerfin SR, Yuan HA, Relley CM. New technologies in spine: kyphoplasty and vertebroplasty for the treatment of painful osteoporotic compression fractures. Spine (Phila Pa 1976). 2001;26(14):1511–5. https://doi.org/10.1097/00007632-200107150-00002.

12. McKernan F, Faciszewski T, Jensen R. Reporting height restoration in vertebroplasty. Orthop Clin North Am. 2018;49(4):467–72. https://doi.org/10.1016/j.ocl.2018.05.003.

13. Christakos S, Li S, Nakamura Y, Kato H. Risk factors of adjacent vertebral collapse after percutaneous vertebroplasty: biomechanical behavior under repetitive loading conditions. Spine (Phila Pa 1976). 2006;31(18):2079–84. https://doi.org/10.1097/01.brs.000023174.15876.76.

14. Li D, Wu Y, Huang Y, Augustin B, Yue J. Risk factors of recompression of cemented vertebrae after kyphoplasty for osteoporotic vertebral compression fractures. J Orthop Surg Res. 2019;14(1):299. https://doi.org/10.1186/s13018-019-1350-3.

15. Horwitz MJ, Augustin M, Khan L, Martin E, Oakley CC, Carneiro RM, Tedesco MB, Laslavl ć A, Sereika SM, Bissel A, Garcia-Ocana A, Gundberg CM, Cauley JA, Stewart AF. A comparison of parathyroid hormone-related protein (1–36) and parathyroid hormone (1–34) on markers of bone turnover and bone density in postmenopausal women: the ProP study. J Bone Miner Res. 2013;28(11):2266–76. https://doi.org/10.1002/jbmr.2128.

16. Hodskin AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, Mcclung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev. 2005;26(5):688–703. https://doi.org/10.1210/er.2004-0006.

17. Anastasialakis AD, Goulis DG, Polyzos SA, Gerou S, Pavlidou V, Kroukoulis S, Arvanitis D. Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappaB ligand levels in women with established osteoporosis treated with teriparatide. Eur J Endocrinol. 2008;158(3):411–5. https://doi.org/10.1530/EJE-07-0528.

18. Yang Y, Zhang XJ, Zhu XJ, Zhang L, Bao MJ, Xian Y, Wu JC, Liu LM, Li PQ. Comparison between recombinant human parathyroid hormone (1–34) and elcatonin in treatment of primary osteoporosis. Asian Pac J Trop Med. 2015;8(1):79–84. https://doi.org/10.1016/S1995-7645(14)60192-9.

19. Ban ZN, Li ZJ, Gu QS, Cheng J, Huang Q, Xing SX. Correlation of serum PTH level and fracture healing speed in elderly patients with hip fracture. J Orthop Surg Res. 2019;14(1):361. https://doi.org/10.1186/s13018-019-1413-5.

20. Lin H, Liu H, Qin L, Tamasi J, Bergenstock M, Shaptes S, Feyen JH, Noterman DA, Partridge NC. Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. J Biol Chem. 2007;282(45):33086–97. https://doi.org/10.1074/jbc.M705194200.

21. Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism. Lancet. 2018;391(10116):168–78. https://doi.org/10.1016/S0140-6736(17)31430-7.

22. Alim M, Alim MA, Khan OA, Alim MF, Khan MA. Effect of vitamin D on bone mineral density: a Mendelian randomization study. J Clin Endocrinol Metab. 2020. https://doi.org/10.1210/clinem/dgaa579.

23. Gao C, Qiao J, Li SS, Yu WJ, He JW, Fu WZ, Zheng ZL. The levels of bone turnover markers 25(OH)D and PTH and their relationship with bone mineral density in postmenopausal women in a suburban district in China. Osteoporos Int. 2017;28(1):111–8. https://doi.org/10.1007/s00198-016-3692-6.

24. Christakos S, Li S, Dela CJ, Verlinden L, Carmeliet G, Vitamin D and bone. Handb Exp Pharmacol. 2020;262:47–63. https://doi.org/10.1007/164_2019_338.

25. Martinez-Ferrer A, Blasco J, Carrasco JL, Macho JM, Roman LS, Lopez A, Monegal A, Guanabens N, Peris P. Risk factors for the development of vertebral fractures after percutaneous vertebroplasty. J Bone Miner Res. 2013;28(8):1821–9. https://doi.org/10.1002/jbmr.1899.

26. Marijnissen E, Teulings MA, Wiersma C, Keizer M, van de Ven NP, Huijing PA, Verhaar J. Leverage phenomenon during rehabilitation after lower limb fractures. J Bone Joint Surg Br. 2019;91(10):1001–5. https://doi.org/10.1302/0301-620X-BJJSB.2019-B00683.

27. Odendaal W, Hillier S, Gray J, Verhaar J. Factors associated with pain in patients with osteoporotic vertebral fracture. J Bone Joint Surg Br. 2017;99(9):782–8. https://doi.org/10.1302/0301-620X-BJJSB.2017-B00696.

28. Lin et al. Journal of Orthopaedic Surgery and Research          (2022) 17:202